Literature DB >> 9332499

Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin.

C M Palmeira1, J Serrano, D W Kuehl, K B Wallace.   

Abstract

The purpose of this investigation was to determine whether acute doxorubicin intoxication causes a preferential accumulation of 8-hydroxydeoxyguanosine (8OHdG) adducts to mitochondrial DNA (mtDNA) as opposed to nuclear DNA (nDNA), particularly in cardiac tissue. Adult male rats received a single i.p. bolus of doxorubicin (15 mg/kg) and were killed 1-14 days later. Acute intoxication with doxorubicin caused a 2-fold greater increase in 8OHdG adducts to mtDNA compared to nDNA, the concentration of adducts to both nDNA and mtDNA being 20%-40% greater for heart as opposed to liver. For both tissues, the relative abundance of adducts was highest at the earliest time-point examined (24 h) and decreased to control values by 2 weeks. The temporal dilution of 8OHdG adducts was not the result of cell hyperplasia and was only partially due to amplification of the mitochondrial genome, most probably via an increase in DNA copy number rather than a stimulation of mitochondrial biogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9332499     DOI: 10.1016/s0005-2728(97)00055-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  18 in total

Review 1.  Mitochondrial DNA damage and its consequences for mitochondrial gene expression.

Authors:  Susan D Cline
Journal:  Biochim Biophys Acta       Date:  2012-06-19

2.  Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice.

Authors:  Natalia Papeta; Zongyu Zheng; Eric A Schon; Sonja Brosel; Mehmet M Altintas; Samih H Nasr; Jochen Reiser; Vivette D D'Agati; Ali G Gharavi
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

3.  Phenyl-alpha-tert-butyl nitrone reverses mitochondrial decay in acute Chagas' disease.

Authors:  Jian-Jun Wen; Vandanajay Bhatia; Vsevolod L Popov; Nisha Jain Garg
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

4.  Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice.

Authors:  Vinodkumar B Pillai; Samik Bindu; Will Sharp; Yong Hu Fang; Gene Kim; Madhu Gupta; Sadhana Samant; Mahesh P Gupta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-02-12       Impact factor: 4.733

5.  Methylmercury induces oxidative injury, alterations in permeability and glutamine transport in cultured astrocytes.

Authors:  Zhaobao Yin; Dejan Milatovic; Judy L Aschner; Tore Syversen; Joao B T Rocha; Diogo O Souza; Marta Sidoryk; Jan Albrecht; Michael Aschner
Journal:  Brain Res       Date:  2006-12-19       Impact factor: 3.252

6.  Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.

Authors:  Salim Khiati; Ilaria Dalla Rosa; Carole Sourbier; Xuefei Ma; V Ashutosh Rao; Leonard M Neckers; Hongliang Zhang; Yves Pommier
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

7.  Cardiac overexpression of 8-oxoguanine DNA glycosylase 1 protects mitochondrial DNA and reduces cardiac fibrosis following transaortic constriction.

Authors:  Jianxun Wang; Qianwen Wang; Lewis J Watson; Steven P Jones; Paul N Epstein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-26       Impact factor: 4.733

8.  Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib.

Authors:  Janusz Blasiak; Grazyna Hoser; Jolanta Bialkowska-Warzecha; Elzbieta Pawlowska; Tomasz Skorski
Journal:  Biores Open Access       Date:  2015-07-01

Review 9.  Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy.

Authors:  Garth L Nicolson; Kenneth A Conklin
Journal:  Clin Exp Metastasis       Date:  2007-12-05       Impact factor: 5.150

10.  Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific.

Authors:  Gonçalo C Pereira; Susana P Pereira; Claudia V Pereira; José A Lumini; José Magalhães; António Ascensão; Maria S Santos; António J Moreno; Paulo J Oliveira
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.